TGI 5
Alternative Names: TGI-5Latest Information Update: 05 Jan 2023
At a glance
- Originator TG ImmunoPharma
- Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immune checkpoint protein inhibitors; Lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 27 Dec 2022 TGI 5 is available for licensing as of 27 Dec 2022. https://www.tgimmunopharma.com/partnerships
- 27 Dec 2022 Preclinical trials in Cancer in China (Parenteral) prior to December 2022 (TG ImmunoPharma website, December 2022)